tetano
Editor, Senior Moderator
J Med Virol
. 2025 May;97(5):e70349.
doi: 10.1002/jmv.70349. Impact of High-Titer Convalescent Plasma on Clinical and Virologic Outcomes Among Veterans Hospitalized With SARS-CoV-2 Infection: VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1)
Edward N Janoff[SUP] 1 2 [/SUP], Mei-Chiung Shih[SUP] 3 4 [/SUP], Curtis Donskey[SUP] 5 6 [/SUP], Ilana Belitskaya-Levy[SUP] 3 [/SUP], Norbert Brau[SUP] 7 8 [/SUP], Maria C Rodriguez-Barradas[SUP] 9 [/SUP], Ernest Chan[SUP] 5 [/SUP], Peter Zimmerman[SUP] 5 [/SUP], Elliott K Miller[SUP] 10 [/SUP], Leroy B Vaughan[SUP] 11 [/SUP], J Daniel Markley[SUP] 11 [/SUP], Alexa M Goldberg[SUP] 10 [/SUP], Peruvemba Sriram[SUP] 12 [/SUP], Antonio Anzueto[SUP] 13 [/SUP], Lauren Uyeda[SUP] 3 [/SUP], Lisa Zehm[SUP] 3 [/SUP], Ashlea Wills[SUP] 1 [/SUP], Caitlin Hutchinson[SUP] 1 [/SUP], Lucas Jones[SUP] 5 6 [/SUP], Dianne Peterson[SUP] 14 [/SUP], Robert J Ringer[SUP] 14 [/SUP], Larry Dumont[SUP] 15 [/SUP], Theresa Gleason[SUP] 16 [/SUP], Robert A Bonomo[SUP] 5 6 [/SUP], Jeffrey L Curtis[SUP] 17 18 [/SUP], Sheldon T Brown[SUP] 7 8 [/SUP]; CURES‐1 Trials Consortium
Affiliations
In the initial absence of proven therapies, empirical COVID-19 convalescent plasma (CCP) was rapidly introduced for individuals hospitalized for COVID-19. Seventy-five participants were randomized from November 2020 to June 2021 in a double-blind, multi-site, placebo-controlled, randomized trial (VA CURES-1) evaluating the impact of CCP vs. saline in Veterans hospitalized with COVID-19 with hypoxemia. The composite primary outcome was acute hypoxemic respiratory failure or all-cause death by Day 29. We analyzed clinical outcomes, nasal viral RNA, plasma cytokines and viral evolution over time. Among 40 participants receiving saline and 35 receiving CCP with high neutralizing titers (median 1:1420), the percent reaching the primary outcome was similar (10%), as were time to clinical recovery and to nasal viral clearance. By whole genome sequencing, viral molecular complexity evolved pre- to posttreatment more frequently in recipients of saline vs. CCP (4 of 7 (57.1%) vs. 1 of 4 (25%), respectively), based on numbers of mixed allele positions. Numbers of amino acid-changing, non-synonymous mutations in the spike protein were greater in saline vs. CCP recipients. Both outcomes suggested purifying selection (reduced overall viral infection complexity) following CCP. In conclusion, convalescent plasma showed no significant clinical impact but may influence SARS-CoV-2 complexity. Trial Registration: ClinicalTrials.gov Identifier: NCT04539275.
Keywords: COVID‐19; convalescent plasma; hypoxemia; randomized controlled trial; respiratory failure; viral complexity.
. 2025 May;97(5):e70349.
doi: 10.1002/jmv.70349. Impact of High-Titer Convalescent Plasma on Clinical and Virologic Outcomes Among Veterans Hospitalized With SARS-CoV-2 Infection: VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1)
Edward N Janoff[SUP] 1 2 [/SUP], Mei-Chiung Shih[SUP] 3 4 [/SUP], Curtis Donskey[SUP] 5 6 [/SUP], Ilana Belitskaya-Levy[SUP] 3 [/SUP], Norbert Brau[SUP] 7 8 [/SUP], Maria C Rodriguez-Barradas[SUP] 9 [/SUP], Ernest Chan[SUP] 5 [/SUP], Peter Zimmerman[SUP] 5 [/SUP], Elliott K Miller[SUP] 10 [/SUP], Leroy B Vaughan[SUP] 11 [/SUP], J Daniel Markley[SUP] 11 [/SUP], Alexa M Goldberg[SUP] 10 [/SUP], Peruvemba Sriram[SUP] 12 [/SUP], Antonio Anzueto[SUP] 13 [/SUP], Lauren Uyeda[SUP] 3 [/SUP], Lisa Zehm[SUP] 3 [/SUP], Ashlea Wills[SUP] 1 [/SUP], Caitlin Hutchinson[SUP] 1 [/SUP], Lucas Jones[SUP] 5 6 [/SUP], Dianne Peterson[SUP] 14 [/SUP], Robert J Ringer[SUP] 14 [/SUP], Larry Dumont[SUP] 15 [/SUP], Theresa Gleason[SUP] 16 [/SUP], Robert A Bonomo[SUP] 5 6 [/SUP], Jeffrey L Curtis[SUP] 17 18 [/SUP], Sheldon T Brown[SUP] 7 8 [/SUP]; CURES‐1 Trials Consortium
Affiliations
- PMID: 40400480
- DOI: 10.1002/jmv.70349
In the initial absence of proven therapies, empirical COVID-19 convalescent plasma (CCP) was rapidly introduced for individuals hospitalized for COVID-19. Seventy-five participants were randomized from November 2020 to June 2021 in a double-blind, multi-site, placebo-controlled, randomized trial (VA CURES-1) evaluating the impact of CCP vs. saline in Veterans hospitalized with COVID-19 with hypoxemia. The composite primary outcome was acute hypoxemic respiratory failure or all-cause death by Day 29. We analyzed clinical outcomes, nasal viral RNA, plasma cytokines and viral evolution over time. Among 40 participants receiving saline and 35 receiving CCP with high neutralizing titers (median 1:1420), the percent reaching the primary outcome was similar (10%), as were time to clinical recovery and to nasal viral clearance. By whole genome sequencing, viral molecular complexity evolved pre- to posttreatment more frequently in recipients of saline vs. CCP (4 of 7 (57.1%) vs. 1 of 4 (25%), respectively), based on numbers of mixed allele positions. Numbers of amino acid-changing, non-synonymous mutations in the spike protein were greater in saline vs. CCP recipients. Both outcomes suggested purifying selection (reduced overall viral infection complexity) following CCP. In conclusion, convalescent plasma showed no significant clinical impact but may influence SARS-CoV-2 complexity. Trial Registration: ClinicalTrials.gov Identifier: NCT04539275.
Keywords: COVID‐19; convalescent plasma; hypoxemia; randomized controlled trial; respiratory failure; viral complexity.